mRNA 1440

Drug Profile

mRNA 1440

Alternative Names: H10N8 Antigen mRNA; H10N8 vaccine; VAL 506440

Latest Information Update: 28 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Valera LLC
  • Class Anti-infectives; Antibodies; RNA; RNA vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Influenza A virus infections

Most Recent Events

  • 26 Sep 2017 Pharmacodynamics data from a preclinical trial in Influenza-A virus infections released by Moderna Therapeutics
  • 26 Sep 2017 Moderna Therapeutics completes a phase I trial in Influenza A virus H10N8 subtype (Prevention, In volunteers) in Germany (Parenteral) before September 2017
  • 27 Apr 2017 Safety and immunogenicity data from a phase I trial in Influenza-A virus infections (In volunteers, Prevention) released by Moderna Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top